What does this research mean for the field?

A critical reassessment of clinical trials on antithrombotic agents clarifies their appropriate use, contraindications, and potential dangers in the management of ischemic cerebrovascular disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Review the pathophysiology of thrombogenesis in cerebral ischemia and re-evaluate clinical trial data assessing antithrombotic therapies using modern statistical standards.

January 1, 1977StrokeOpen Access

XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy.

View Full Paper

Ask AI

Bookmark

Why the study?

What is the role and efficacy of antithrombotic therapy in the management of ischemic cerebrovascular disease?

Population

Patients with ischemic cerebrovascular disease (cerebral ischemia and infarction)

Design

Review

Authors

EGEdward GentonUniversity of Colorado Boulder HBHenry J.M. BarnettBoston University WFWilliam S. FieldsThomas Jefferson National Accelerator Facility

Discussion

Member takes

Implication

Reassessment of antithrombotic trials supports cautious use in ischemic stroke; leaves open need for updated randomized evidence.

Key Points

Review the pathophysiology of thrombogenesis in cerebral ischemia and re-evaluate clinical trial data assessing antithrombotic therapies using modern statistical standards.
Synthesized evidence on biological mechanisms governing hemostasis, thrombogenesis, and cerebral infarction.
Critically analyzed historical clinical trials of oral anticoagulants, platelet-suppressant agents (aspirin, dipyridamole, sulfinpyrazone), and thrombolytic agents against modern statistical criteria.
Identified significant interpretive barriers in earlier trials resulting from inconsistent clinical terminology and diagnostic criteria for focal ischemic disease.
Characterized efficacy profiles qualitatively while detailing critical contraindications and safety risks associated with antithrombotic and thrombolytic regimens.

Structured PICO

What is the role and efficacy of antithrombotic therapy in the management of ischemic cerebrovascular disease?

Population

Patients with ischemic cerebrovascular disease (cerebral ischemia and infarction)

Intervention

Antithrombotic therapy (oral anticoagulants, platelet-suppressants including aspirin, dipyridamole, sulfinpyrazone, and thrombolytic agents)

This report provides a critical review of antithrombotic therapies for cerebral ischemia, reassessing historical trial data to guide appropriate clinical use and highlight potential risks.

Cite This Study

Genton et al. (1977) studied this question.

synapsesocial.com/papers/6a1e692a5e142cd49eb09cf1 https://doi.org/10.1161/01.str.8.1.150

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy.

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider